SAN DIEGO, Aug. 19, 2020 /PRNewswire/ -- Aegea
Biotechnologies, Inc. (www.aegeabiotech.com, "Aegea"), a
biotechnology company focusing on the development and
commercialization of next generation nucleic acid and clinical
diagnostic technologies, announces the issuance of US Patent
10,745,749, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE
VARIANTS. The patent provides intellectual property protection for
Primer-Switch technology which is useful for detecting rare genetic
events and for improving real-time PCR amplification reaction as
well as associated analysis methods, including next-generation
sequencing (NGS). Importantly, this patented technology can
also be applied to molecular diagnostic tests for SARS-CoV-2
(COVID-19, coronavirus)
The issuance of this patent expands Aegea's already sizable
intellectual property estate to 11 issued US patents and 33 foreign
equivalents. The Primer-Switch is another method, in addition to
Aegea's Switch-Blocker technology, that can be used for the
detection of important rare genetic events such as, for example,
those associated with cancer causation and drug resistance. The
grant of this US patent represents the second Primer Switch patent
issued to Aegea, and it positions the company for worldwide patent
protection.
Beyond its use for the detection of rare genetic events, the
Primer-Switch technology can be used to enhance the performance and
specificity of PCR amplification reactions, which are widely used
in molecular diagnostic testing, including COVID-19 testing,
hereditary disease testing, environmental testing, and many others.
The Primer-Switch methodology has far reaching applications,
especially where the detection of rare genetic events are needed or
where more precise PCR reactions are required for detecting rare
genetic events, and in cases where more precise PCR amplification
reactions are needed or desired.
"Receiving intellectual property protection for our Primer
Switch technology helps establish our leadership position in
innovative nucleic acid-based diagnostic technologies," said
Lyle J. Arnold, Ph.D., Aegea's
President & CEO.
Stella M. Sung, Ph.D., Chief
Business Officer of Aegea adds, "The Primer Switch is another
powerful tool that can be applied to Aegea's suite of innovative
nucleic acid technologies. Moreover, it is directly
applicable to COVID-19 testing, which is an area that Aegea is
focused on as we develop innovative PCR and point-of-care
diagnostic tests for SARS-CoV-2 and collaborate with partners such
as Tauriga Sciences."
About Aegea Biotechnologies
Aegea Biotechnologies, Inc. located in San Diego, California, is a biotechnology
company focusing on the development and commercialization of next
generation nucleic acid technologies. A primary focus for the
company is nucleic acid technology innovations that embrace
molecular diagnostic assays, qPCR technologies, sequencing methods
including both Sanger and NGS, and
rapid point-of-care COVID-19 testing. Aegea has complementary
collaborations with Biocept (Nasdaq: BIOC) and Tauriga Sciences
(OTC/QB: TAUG) for developing its COVID-19
tests.www.aegeabiotech.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aegea-biotechnologies-inc-announces-the-issuance-of-us-patent-for-primer-switch-nucleic-acid-probes-for-the-detection-of-rare-genetic-events-and-for-pcr-amplification-improvements-301114427.html
SOURCE Aegea Biotechnologies, Inc.